In a nutshell This study evaluated the effectiveness and safety of prophylactic cranial irradiation (PCI) in patients with extensive stage (ES) small cell lung cancer (SCLC). The data indicated that PCI may decrease the occurrence of brain metastases in patients with ES-SCLC and improve 1-year survival time, without improving the overall survival...
Read More
In a nutshell This study investigated the effectiveness and safety outcomes of adebrelimab (SHR-1316) plus carboplatin (Paraplatin) and etoposide (Etopophos)-based chemotherapy as first-line treatment for extensive-stage (ES) small-cell lung cancer (SCLC). The data showed that adebrelimab added to standard chemotherapy as first-line treatment...
Read More
In a nutshell This article looked at the outcomes of patients with extensive-stage (ES) small cell lung cancer (SCLC) treated with atezolizumab (Tecentriq), carboplatin (CP; Paraplatin), and etoposide (ET; Etopophos). The authors found that the addition of atezolizumab to CP/ET chemotherapy improved the outcomes of these...
Read More
In a nutshell This article looked at the use of immune checkpoint inhibitors (ICIs) in the treatment of extensive-stage (ES) small cell lung cancer (SCLC). The authors found that the addition of atezolizumab (Tecentriq) or durvalumab (Imfinzi) to first-line platinum-based chemotherapy prolongs survival and improves the quality of life...
Read More
In a nutshell This trial is examining the effectiveness of atezolizumab (Tecentriq) plus carboplatin (Paraplatin) and etoposide (Etopophos) with or without tiragolumab in patients with untreated extensive-stage small-cell lung cancer (ES-SCLC). The main outcomes that will be measured are progression-free survival (PFS) and overall survival...
Read More
In a nutshell This study examined the effectiveness and safety of adding durvalumab (Imfinzi) to platinum-etoposide to treat patients with small-cell lung carcinoma (SCLC). The authors found that durvalumab was well-tolerated and improved survival outcomes. Some background Small cell lung carcinoma (SCLC) is a type of lung cancer that...
Read MoreIn a nutshell This study wants to find out how well talazoparib (Talzenna) and temozolomide (Temodal) work for treating patients with small cell lung cancer that has come back after or was unresponsive to initial chemotherapy. The main outcome that will be measured is how long the patients go before the cancer grows. The study is...
Read MoreIn a nutshell This trial looked at factors which would help predict whether aggressive radiation would be beneficial to patients with extensive stage small cell lung cancer who have progressed passed chemotherapy. The authors concluded that patients with less than three metastases (spread of cancer) would benefit most. Some background...
Read More
Video information: Are there new developments in treating metastatic lung cancer? Dr. David Carbone of Ohio State University Comprehensive Cancer Center has much to report. From new medications that directly impact quality of life, rapid research to patients who are outliving their original prognosis, Dr. Carbone weighs in on...
Read More
In a nutshell The authors aimed to determine the effects of dalotuzumab in treating small-cell lung cancer when combined with cisplatin and etoposide. Some background Extensive-stage small-cell lung cancer (SCLC – cancer has spread outside of the chest) represents 15% of all lung cancer cases. Though numerous treatments have been used over...
Read More
In a nutshell This review examined the effectiveness of chemotherapy in the treatment of extensive-disease small-cell lung cancer. Some background Small cell lung cancer is an aggressive form of lung cancer, which often progresses very quickly. In the majority of cases the cancer has already metastasized (spread) beyond the lungs by the time of...
Read More
In a nutshell This phase III study compared the benefit of three chemotherapy combinations as first line treatment (the first choice of treatment) for extensive disease small-cell lung cancer (ED-SCLC) patients. Topotecan–cisplatin (TP) combination treatment, topotecan–etoposide (TE) combination treatment, and cisplatin-etoposide (PE)...
Read More
